PELOSI INTRODUCES DRUG PRICING BILL WHILE TRUMP PUSHES SENATE VERSION -
House Democrats introduced legislation last week to lower prescription drug prices – including allowing Medicare to negotiate prices with...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
GRASSLEY CONFIRMS DELAY ON DRUG BILL WHILE ANOTHER COMMITTEE PLANS VOTES -
Senate Finance Committee Chairman...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session....more
6/11/2019
/ Data Breach ,
Data Protection ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Medicare ,
Medicare for All ,
Medicare Part D ,
Pharmaceutical Industry ,
Prescription Drugs ,
Prior Authorization
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
HOUSE TO VOTE ON BILL COMBINING ACA, DRUG PRICING PROVISIONS -
The House is scheduled to vote on legislation...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
TRUMP, DEMOCRATIC LEADERS TO MEET ON DRUG PRICES -
During a White House meeting last week on infrastructure...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
DRUG PRICES: CONGRESS RETURNS, PICKS UP WHERE LAWMAKERS LEFT OFF -
Congress reconvenes today after a...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
HOUSE PANEL TO VOTE ON BIPARTISAN DRUG PRICING MEASURE -
The House Ways and Means Committee is scheduled to...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
REPUBLICANS BALK AT TRUMP’S CALL FOR NEW HEALTHCARE BILL -
President Donald Trump last week said Republicans...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session.
GOTTLIEB, HARGAN TO TESTIFY ON 2020 HEALTH BUDGET, PROGRAMS -
Outgoing FDA Commissioner Scott Gottlieb and...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: Azar testifies before three committees on HHS’ budget; a series of Senate bills targeting...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: PBMs next in Senate committee’s crosshairs; lawmakers continue scrutiny on insulin prices;...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: Pharma industry CEOs testify before a Senate committee; House and Senate panels probe...more
Senate Democrats recently introduced the Stop Price Gouging Act (S. 378), which seeks to place an excise tax on pharmaceutical companies in proportion to price spikes on prescription drugs.
The bill generally requires a...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: shutdown risk increases as talks stall; Gottlieb’s Hill testimony postponed; more bills...more
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: Trump will discuss healthcare and drug costs in this week’s State of the Union address;...more
2/5/2019
/ Affordable Care Act ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Medical Devices ,
Medicare ,
Medicare Part B ,
Medicare Part D ,
Pharmaceutical Industry ,
Preexisting Conditions ,
Prescription Drugs ,
Trump Administration
Below is this week’s “Capitol Hill Healthcare Update,” which is posted on Mondays when Congress is in session. Highlights this week: With the shutdown over (for now), the FDA is back in business; two hearings spotlight drug...more
Highlights this week: Gottlieb warns FDA’s funds running low as shutdown continues; House Dems launch sweeping probe on drug prices, Senate approves Medicaid measures, and more....more
Highlights this week: Nearly 7,000 FDA employees are furloughed amid the ongoing government shutdown; lawmakers introduce a slew of anti-pharma bills; 18 new Democrats land plum spots on key healthcare committees; and more....more
Highlights this week: how the partial government shutdown is affecting operations at the FDA; House Democrats take steps to defend the ACA; the House votes this week to renew emergency health response programs; new senators...more
Highlights this week include a lame duck update on year-end health bills and tax provisions; lawmakers reacting to a federal judge ruling the Affordable Care Act is unconstitutional; Sen. Hatch seeks to update Hatch-Waxman;...more
12/17/2018
/ Affordable Care Act ,
Congressional Budget Office ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Furloughs ,
Government Shutdown ,
Medicare Part D ,
Patents ,
Pharmaceutical Industry ,
Trump Administration ,
USPTO
Highlights this week: Lawmakers renew efforts to avoid a partial government shutdown, which would affect FDA; key senators introduce legislation on Medicaid prescription drug rebates; the House votes this week on allowing...more
Highlights this week: Healthcare legislative priorities are caught up in a separate spending debate that could lead to a partial government shutdown; some GOP lawmakers push back on Trump’s Part B pilot program; a key...more
Highlights this week: Democrats’ takeover of the House will yield big changes for healthcare policy in 2019; several GOP lawmakers active in healthcare policy are defeated; pharma pushes for Part D changes in the lame duck;...more
11/13/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Lame Duck Session ,
Medical Devices ,
Medicare ,
Medicare Part A ,
Medicare Part D ,
Pharmaceutical Industry ,
Prescription Drug Coverage
Democrats’ slender majority in the House next year will have an outsized impact on healthcare policy and healthcare stakeholders in 2019 and beyond. From potential bipartisan deals on prescription drug prices to Democrats’...more
Included this week is an update on congressional efforts to finish opioids response legislation; efforts by pharmaceutical manufacturers to change discounts they are required to provide Medicare beneficiaries in the Part D...more